IP Library Granted Patent US 12,533,331
Granted Patent B2
US 12,533,331 · App. 18/907,258 · Granted Jan 27, 2026

S-beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies

Inventor: Gary Millet (Salt Lake City, UT)
Assignee: AXCESS GLOBAL SCIENCES, LLC
A61K31/19A61K31/121A23V2200/3322
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,533,331
App. No.
18/907,258
Granted
Jan 27, 2026
Kind
B2
Abstract

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and/or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

Claims (33)

1 . An aqueous beta-hydroxybutyric acid composition formulated as a nutritional supplement, or for addition to water, beverage, or food product, for ingestion by oral delivery to provide exogenous ketone bodies that exogenously increase blood ketone level in a mammal, the composition comprising:

water; and

0.4% w/v to 55% w/v of exogenous beta-hydroxybutyric acid in monomeric form at least partially dissolved in the water,

wherein the exogenous beta-hydroxybutyric acid is enantiomerically pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid so as to include at least 60% by enantiomeric equivalents of S-beta-hydroxybutyric acid and no more than 40% by enantiomeric equivalents of R-beta-hydroxybutyric acid.

2 . The aqueous beta-hydroxybutyric acid composition of claim 1 , wherein the composition is a dilute solution in which the exogenous beta-hydroxybutyric acid has a concentration of about 0.4% w/v to about 6% w/v, or about 0.6% w/v to about 5.5% w/v, or about 0.9% w/v to about 5% w/v, or about 1.2% w/v to about 4.5% w/v, or about 1.5% w/v to about 4% w/v.

3 . The aqueous beta-hydroxybutyric acid composition of claim 1 , wherein about 4 oz. (about 120 ml) to about 16 oz. (about 475 ml) of the composition provides the unit dose of about 0.5 gram to about 25 grams, or about 0.75 gram to about 20 grams, or about 1 gram to about 15 grams, or about 1.5 grams to about 12 grams, or about 2 grams to about 10 grams, of the exogenous beta-hydroxybutyrate to the mammal when consumed orally.

4 . The aqueous beta-hydroxybutyric acid composition of claim 1 , wherein the composition is a concentrated solution for addition to water, beverage, or food product in which the exogenous beta-hydroxybutyric acid has a concentration of about 6% w/v to about 55% w/v, or about 8% w/v to about 55% w/v, or about 10% w/v to about 50% w/v, or about 12.5% w/v to about 45% w/v, or about 15% w/v to about 40% w/v.

5 . The aqueous beta-hydroxybutyric acid composition of claim 1 , wherein the exogenous beta-hydroxybutyric acid contains at least 90% by enantiomeric equivalents of S-beta-hydroxybutyric acid and no more than 10% by enantiomeric equivalents of R-beta-hydroxybutyric acid.

6 . The aqueous beta-hydroxybutyric acid composition of claim 1 , wherein the composition is a gel and further comprises at least one gelling agent.

7 . The aqueous beta-hydroxybutyric acid composition of claim 1 , further comprising S-1,3-butanediol.

8 . The aqueous beta-hydroxybutyric acid composition of claim 1 , further comprising an enantiomerically pure S-beta-hydroxybutyrate ester or salt or a non-racemic mixture enriched with S-beta-hydroxybutyrate ester or salt relative to R-beta-hydroxybutyrate ester or salt so as to include at least 60% by enantiomeric equivalents of S-beta-hydroxybutyrate ester or salt and no more than 40% by enantiomeric equivalents of R-beta-hydroxybutyrate ester or salt.

9 . The aqueous beta-hydroxybutyric acid composition of claim 8 , wherein the composition comprises less than 4% of beta-hydroxybutyrate salts by combined weight of beta-hydroxybutyric acid and any beta-hydroxybutyrate salts in the composition.

10 . An aqueous beta-hydroxybutyric acid composition in the form of a nutritional beverage supplement for ingestion by oral delivery to provide exogenous ketone bodies that exogenously increase blood ketone level in a mammal, the composition comprising:

water; and

0.4% w/v to 5% w/v of exogenous beta-hydroxybutyric acid in monomeric form dissolved in the water to form an aqueous solution,

wherein the exogenous beta-hydroxybutyric acid is enantiomerically pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid so as to include at least 60% by enantiomeric equivalents of S-beta-hydroxybutyric acid and no more than 40% by enantiomeric equivalents of R-beta-hydroxybutyric acid.

11 . The aqueous beta-hydroxybutyric acid composition of claim 10 , wherein the beta-hydroxybutyric acid has a concentration of about 0.6% w/v to about 5.5% w/v, or about 0.9% w/v to about 5% w/v, or about 1.2% w/v to about 4.5% w/v, or about 1.5% w/v to about 4% w/v.

12 . The aqueous beta-hydroxybutyric acid composition of claim 10 , wherein about 4 oz. (about 120 ml) to about 16 oz. (about 475 ml) of the composition provides the unit dose of about 0.5 gram to about 25 grams, or about 0.75 gram to about 20 grams, or about 1 gram to about 15 grams, or about 1.5 grams to about 12 grams, or about 2 grams to about 10 grams, of the exogenous beta-hydroxybutyrate to the mammal when consumed orally.

13 . The aqueous beta-hydroxybutyric acid composition of claim 10 , wherein the exogenous beta-hydroxybutyric acid includes at least 90% by enantiomeric equivalents of S-beta-hydroxybutyric acid and no more than 10% by enantiomeric equivalents of R-beta-hydroxybutyric acid.

14 . The aqueous beta-hydroxybutyric acid composition of claim 10 , further comprising S-1,3-butanediol.

15 . The aqueous beta-hydroxybutyric acid composition of claim 10 , further comprising an enantiomerically pure S-beta-hydroxybutyrate ester or salt or a non-racemic mixture enriched with S-beta-hydroxybutyrate ester or salt relative to R-beta-hydroxybutyrate ester or salt so as to include at least 60% by enantiomeric equivalents of S-beta-hydroxybutyrate ester or salt and no more than 40% by enantiomeric equivalents of R-beta-hydroxybutyrate ester or salt.

16 . The aqueous beta-hydroxybutyric acid composition of claim 15 , wherein the composition comprises less than 4% of beta-hydroxybutyrate salts by combined weight of beta-hydroxybutyric acid and any beta-hydroxybutyrate salts in the composition.

17 . An aqueous beta-hydroxybutyric acid composition in the form of a concentrated solution that can be added to water, beverage, or food to form an edible nutritional supplement for ingestion by oral delivery to provide exogenous ketone bodies that exogenously increase blood ketone level in a mammal, the composition comprising:

water; and

about 6% w/v to about 55% w/v of exogenous beta-hydroxybutyric acid in monomeric form at least partially dissolved in the water,

wherein the exogenous beta-hydroxybutyric acid is enantiomerically pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid so as to include at least 60% by enantiomeric equivalents of S-beta-hydroxybutyric acid and no more than 40% by enantiomeric equivalents of R-beta-hydroxybutyric acid.

18 . The aqueous beta-hydroxybutyric acid composition of claim 17 , wherein the exogenous beta-hydroxybutyric acid has a concentration of about 8% w/v to about 55% w/v, or about 10% w/v to about 50% w/v, or about 12.5% w/v to about 45% w/v, or about 15% w/v to about 40% w/v.

19 . The aqueous beta-hydroxybutyric acid composition of claim 17 , wherein the exogenous beta-hydroxybutyric acid includes at least 90% by enantiomeric equivalents of S-beta-hydroxybutyric acid and no more than 10% by enantiomeric equivalents of R-beta-hydroxybutyric acid.

20 . The aqueous beta-hydroxybutyric acid composition of claim 17 , further comprising at least one of:

S-1,3-butanediol;

an enantiomerically pure S-beta-hydroxybutyrate ester or a non-racemic mixture enriched with S-beta-hydroxybutyrate ester relative to R-beta-hydroxybutyrate ester so as to include at least 60% by enantiomeric equivalents of S-beta-hydroxybutyrate ester and no more than 40% by enantiomeric equivalents of R-beta-hydroxybutyrate ester; or

an enantiomerically pure S-beta-hydroxybutyrate salt or a non-racemic mixture enriched with S-beta-hydroxybutyrate salt relative to R-beta-hydroxybutyrate salt so as to include at least 60% by enantiomeric equivalents of S-beta-hydroxybutyrate salt and no more than 40% by enantiomeric equivalents of R-beta-hydroxybutyrate salt.

21 . The aqueous beta-hydroxybutyric acid composition of claim 17 , wherein the composition comprises less than 4% of beta-hydroxybutyrate salts by combined weight of beta-hydroxybutyric acid and any beta-hydroxybutyrate salts in the composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2024
From: MILLET, GARY
To: AXCESS GLOBAL SCIENCES, LLC
Reel/Frame 068831/0645 →
Continuity (26)
Continuation 18217111 · Jun 30, 2023
Continuation In Part 17210646 · Mar 24, 2021
Continuation In Part 17190062 · Mar 2, 2021
Continuation In Part 17157000 · Jan 25, 2021
Continuation In Part 17130498 · Dec 22, 2020
Continuation In Part 16996509 · Aug 18, 2020
Continuation In Part 16783886 · Feb 6, 2020
Continuation In Part 16783956 · Feb 6, 2020
Continuation In Part 16783907 · Feb 6, 2020
Continuation In Part 16783844 · Feb 6, 2020
Continuation In Part 16720211 · Dec 19, 2019
Continuation In Part 16551570 · Aug 26, 2019
Continuation In Part 16551594 · Aug 26, 2019
Continuation 16381202 · Apr 11, 2019
Continuation In Part 16272359 · Feb 11, 2019
Continuation In Part 16272328 · Feb 11, 2019
Provisional Application 63070532 · Aug 26, 2020
Provisional Application 62805054 · Feb 13, 2019
Provisional Application 62769432 · Nov 19, 2018
Provisional Application 62769412 · Nov 19, 2018
Provisional Application 62760462 · Nov 13, 2018
Provisional Application 62760430 · Nov 13, 2018
Provisional Application 62723274 · Aug 27, 2018
Provisional Application 62723283 · Aug 27, 2018
Provisional Application 62659564 · Apr 18, 2018
Related Publication 20250025434A1 · Jan 23, 2025
References Cited (400)
US 2238149A · Aeckerle · 1941 [cited by applicant]
US 2976073A · Russell et al. · 1961 [cited by applicant]
US 4139761A · Obrowski · 1979 [cited by applicant]
US 4224503A · Gijzel et al. · 1980 [cited by applicant]
US 4292499A · Kleinschmidt et al. · 1981 [cited by applicant]
US 4627808A · Hughes · 1986 [cited by applicant]
US 4663166A · Veech · 1987 [cited by applicant]
US 4771074A · Lammerant et al. · 1988 [cited by applicant]
US 4969393A · Mahlich et al. · 1990 [cited by applicant]
US 4997976A · Brunengraber et al. · 1991 [cited by applicant]
US 5093044A · Wretlind et al. · 1992 [cited by applicant]
US 5100677A · Veech · 1992 [cited by applicant]
US 5116868A · Chen et al. · 1992 [cited by applicant]
US 5288512A · Seiden · 1994 [cited by applicant]
US 5292774A · Hiraide et al. · 1994 [cited by applicant]
US 5654266A · Chen et al. · 1997 [cited by applicant]
US 5700670A · Yamagishi et al. · 1997 [cited by applicant]
US 6031000A · Nissen et al. · 2000 [cited by applicant]
US 6207856B1 · Veech · 2001 [cited by applicant]
US 6217915B1 · Luchansky et al. · 2001 [cited by applicant]
US 6232345B1 · Hiraide et al. · 2001 [cited by applicant]
US 6316038B1 · Veech · 2001 [cited by applicant]
US 6323237B1 · Veech · 2001 [cited by applicant]
US 6380244B2 · Martin et al. · 2002 [cited by applicant]
US 6613356B1 · Vlahakos · 2003 [cited by applicant]
US 6706756B1 · Fitzpatrick et al. · 2004 [cited by applicant]
US 6835750B1 · Henderson · 2004 [cited by applicant]
US 7351736B2 · Veech · 2008 [cited by applicant]
US 7807718B2 · Hashim et al. · 2010 [cited by applicant]
US 7891287B2 · Miller · 2011 [cited by applicant]
US 8071641B2 · Weiss et al. · 2011 [cited by applicant]
US 8101653B2 · Veech · 2012 [cited by applicant]
US 8124589B2 · Henderson · 2012 [cited by applicant]
US 8344896B2 · Ozanne · 2013 [cited by applicant]
US 8426468B2 · Henderson · 2013 [cited by applicant]
US 8642654B2 · Clarke et al. · 2014 [cited by applicant]
US 8748400B2 · Henderson · 2014 [cited by applicant]
US 9138420B2 · D'Agostino et al. · 2015 [cited by applicant]
US 9186340B2 · Andrews et al. · 2015 [cited by applicant]
US 9211275B2 · Clarke et al. · 2015 [cited by applicant]
US 9435566B2 · Hill et al. · 2016 [cited by applicant]
US 9675577B2 · D'Agostino et al. · 2017 [cited by applicant]
US 9717767B2 · Carpenter et al. · 2017 [cited by applicant]
US 9795580B2 · Weeber et al. · 2017 [cited by applicant]
US 9808481B2 · Ritter et al. · 2017 [cited by applicant]
US 9925164B1 · Hashim · 2018 [cited by applicant]
US 9957246B2 · Stinchcomb et al. · 2018 [cited by applicant]
US 10022409B2 · Carpenter et al. · 2018 [cited by applicant]
US 10051880B2 · Clarke et al. · 2018 [cited by applicant]
US 10088197B2 · Hamagami et al. · 2018 [cited by applicant]
US 10245242B1 · Millet · 2019 [cited by applicant]
US 10245243B1 · Millet · 2019 [cited by applicant]
US 10278961B2 · Lowery et al. · 2019 [cited by applicant]
US 10292592B2 · Marshall et al. · 2019 [cited by applicant]
US 10292952B2 · Millet · 2019 [cited by applicant]
US 10407331B2 · Kamito et al. · 2019 [cited by applicant]
US 10512615B1 · Millet · 2019 [cited by applicant]
US 10588876B2 · Millet · 2020 [cited by applicant]
US 10588877B2 · Arnold · 2020 [cited by applicant]
US 10596128B2 · Millet · 2020 [cited by applicant]
US 10596129B2 · Millet · 2020 [cited by applicant]
US 10596130B2 · Millet · 2020 [cited by applicant]
US 10596131B2 · Millet · 2020 [cited by applicant]
US 10660958B2 · Clarke · 2020 [cited by applicant]
US 10736861B2 · Millet · 2020 [cited by applicant]
US 10792269B2 · Hashim · 2020 [cited by applicant]
US 10925843B2 · Millet · 2021 [cited by applicant]
US 10973786B2 · Millet · 2021 [cited by applicant]
US 10980764B1 · D'Agostino et al. · 2021 [cited by applicant]
US 10980772B2 · Millet · 2021 [cited by applicant]
US 11020362B2 · Millet · 2021 [cited by applicant]
US 11026929B2 · Lowery et al. · 2021 [cited by applicant]
US 11033553B2 · Millet · 2021 [cited by applicant]
US 11103470B2 · Millet · 2021 [cited by applicant]
US 11129802B2 · Millet · 2021 [cited by applicant]
US 11173138B2 · Lowery et al. · 2021 [cited by applicant]
US 11185518B2 · Millet · 2021 [cited by applicant]
US 11202769B2 · Millet · 2021 [cited by applicant]
US 11241403B2 · Millet · 2022 [cited by applicant]
US 11690817B2 · Millet · 2023 [cited by applicant]
US 11793778B2 · Millet · 2023 [cited by applicant]
US 11806324B2 · Millet · 2023 [cited by applicant]
US 11944598B2 · Millet · 2024 [cited by applicant]
US 11950616B2 · Millet · 2024 [cited by applicant]
US 11969411B2 · Lowery et al. · 2024 [cited by applicant]
US 12186297B2 · Millet · 2025 [cited by applicant]
US 12251362B2 · Lowery et al. · 2025 [cited by applicant]
US 12350243B2 · Millet et al. · 2025 [cited by applicant]
US 20010014696A1 · Veech · 2001 [cited by applicant]
US 20010018866A1 · Fischer · 2001 [cited by applicant]
US 20010041736A1 · Veech · 2001 [cited by applicant]
US 20020013339A1 · Martin et al. · 2002 [cited by applicant]
US 20020124370A1 · Deckert et al. · 2002 [cited by applicant]
US 20030022937A1 · Veech · 2003 [cited by applicant]
US 20040126366A1 · Kaddurah-Daouk et al. · 2004 [cited by applicant]
US 20040138293A1 · Werner et al. · 2004 [cited by applicant]
US 20040266872A1 · Veech · 2004 [cited by applicant]
US 20050129783A1 · Mccleary et al. · 2005 [cited by applicant]
US 20050169968A1 · Elmaleh et al. · 2005 [cited by applicant]
US 20060165777A1 · Solomon et al. · 2006 [cited by applicant]
US 20060275253A1 · Ushida et al. · 2006 [cited by applicant]
US 20070029913A1 · Chen · 2007 [cited by applicant]
US 20070135376A1 · Henderson · 2007 [cited by applicant]
US 20070179197A1 · Henderson · 2007 [cited by applicant]
US 20080058416A1 · Greenwood et al. · 2008 [cited by applicant]
US 20080287372A1 · Henderson · 2008 [cited by applicant]
US 20090131475A1 · Uesugi et al. · 2009 [cited by applicant]
US 20090253781A1 · Veech · 2009 [cited by applicant]
US 20090306221A1 · Guy et al. · 2009 [cited by applicant]
US 20090325984A1 · Costentin et al. · 2009 [cited by applicant]
US 20100041751A1 · Henderson · 2010 [cited by applicant]
US 20100056631A1 · Hisamura et al. · 2010 [cited by applicant]
US 20100113494A1 · Hu et al. · 2010 [cited by applicant]
US 20100197758A1 · Andrews et al. · 2010 [cited by applicant]
US 20100210726A1 · Kuriyama · 2010 [cited by applicant]
US 20100298294A1 · Clarke et al. · 2010 [cited by applicant]
US 20110111049A1 · Andrews et al. · 2011 [cited by applicant]
US 20110237666A1 · Clarke et al. · 2011 [cited by applicant]
US 20110287114A1 · Johnson · 2011 [cited by applicant]
US 20120053240A1 · Rathmacher et al. · 2012 [cited by applicant]
US 20120071548A1 · Veech · 2012 [cited by applicant]
US 20120171165A1 · Buck et al. · 2012 [cited by applicant]
US 20120202891A1 · Stinchcomb et al. · 2012 [cited by applicant]
US 20130079406A1 · Veech · 2013 [cited by applicant]
US 20130337116A1 · Petralia · 2013 [cited by applicant]
US 20140256808A1 · Henderson · 2014 [cited by applicant]
US 20140329893A1 · Veech · 2014 [cited by applicant]
US 20140350105A1 · D'Agostino et al. · 2014 [cited by applicant]
US 20140352728A1 · Svensson · 2014 [cited by applicant]
US 20150018415A1 · Veech · 2015 [cited by applicant]
US 20150063140A1 · Yi et al. · 2015 [cited by applicant]
US 20150065571A1 · Clarke et al. · 2015 [cited by applicant]
US 20150132280A1 · Lopez et al. · 2015 [cited by applicant]
US 20150144074A1 · Fujimoto et al. · 2015 [cited by applicant]
US 20150320809A1 · Carpenter et al. · 2015 [cited by applicant]
US 20150363750A1 · Svensson et al. · 2015 [cited by applicant]
US 20160193173A1 · Clarke et al. · 2016 [cited by applicant]
US 20160256411A1 · Aung-Din · 2016 [cited by applicant]
US 20160263071A1 · Borges et al. · 2016 [cited by applicant]
US 20160272603A1 · Kravchenko et al. · 2016 [cited by applicant]
US 20170020844A1 · Galinski · 2017 [cited by applicant]
US 20170029650A1 · Veling et al. · 2017 [cited by applicant]
US 20170172969A1 · D'Agostino et al. · 2017 [cited by applicant]
US 20170258745A1 · Millet · 2017 [cited by applicant]
US 20170266148A1 · D'Agostino et al. · 2017 [cited by applicant]
US 20170290792A1 · Cavaleri · 2017 [cited by applicant]
US 20170296501A1 · Lowery et al. · 2017 [cited by applicant]
US 20170296520A1 · Lowery et al. · 2017 [cited by applicant]
US 20170298339A1 · Hanson et al. · 2017 [cited by applicant]
US 20170304564A1 · Dehaan et al. · 2017 [cited by applicant]
US 20180020699A1 · Steup · 2018 [cited by applicant]
US 20180021274A1 · Arnold · 2018 [cited by applicant]
US 20180021281A1 · Berger · 2018 [cited by applicant]
US 20180055797A1 · Llosa et al. · 2018 [cited by applicant]
US 20180057846A1 · Llosa et al. · 2018 [cited by applicant]
US 20180195096A1 · Veech et al. · 2018 [cited by applicant]
US 20180214399A1 · Spector et al. · 2018 [cited by applicant]
US 20180238586A1 · Sugatani et al. · 2018 [cited by applicant]
US 20190099394A1 · Ari et al. · 2019 [cited by applicant]
US 20190151267A1 · Millet · 2019 [cited by applicant]
US 20190167613A1 · Millet · 2019 [cited by applicant]
US 20190167614A1 · Millet · 2019 [cited by applicant]
US 20190177673A1 · Llosa et al. · 2019 [cited by applicant]
US 20190183220A1 · Takada · 2019 [cited by applicant]
US 20190183820A1 · Millet · 2019 [cited by applicant]
US 20190183821A1 · Millet · 2019 [cited by applicant]
US 20190191755A1 · Garvey et al. · 2019 [cited by applicant]
US 20190209501A1 · Tinsley et al. · 2019 [cited by applicant]
US 20190255028A1 · Lowery et al. · 2019 [cited by applicant]
US 20190262293A1 · Millet · 2019 [cited by applicant]
US 20190313682A1 · Nagel · 2019 [cited by applicant]
US 20190321309A1 · Millet · 2019 [cited by applicant]
US 20200030266A1 · Bradley et al. · 2020 [cited by applicant]
US 20200061004A1 · Millet · 2020 [cited by applicant]
US 20200078973A1 · Valeze et al. · 2020 [cited by applicant]
US 20200129463A1 · Lowery et al. · 2020 [cited by applicant]
US 20200140371A1 · Verdin et al. · 2020 [cited by applicant]
US 20200170982A1 · Millet · 2020 [cited by applicant]
US 20200253909A1 · Millet · 2020 [cited by applicant]
US 20200268701A1 · D'Agostino et al. · 2020 [cited by applicant]
US 20200276203A1 · Larocca et al. · 2020 [cited by applicant]
US 20210095867A1 · Gururaja et al. · 2021 [cited by applicant]
US 20210106168A1 · Cingolani et al. · 2021 [cited by applicant]
US 20210205241A1 · Millet · 2021 [cited by applicant]
US 20220133673A1 · Millet · 2022 [cited by applicant]
US 20220202760A1 · Greenwood et al. · 2022 [cited by applicant]
US 20230072854A1 · Purpura et al. · 2023 [cited by applicant]
US 20230115966A1 · Wells et al. · 2023 [cited by applicant]
US 20230201145A1 · Gary · 2023 [cited by applicant]
US 20230346721A1 · Millet · 2023 [cited by examiner]
US 20240024265A1 · Millet · 2024 [cited by applicant]
US 20240197668A1 · Millet · 2024 [cited by applicant]
CA 2990927A1 · 2018 [cited by applicant]
CN 86108978A · 1987 [cited by applicant]
CN 1256629A · 2000 [cited by applicant]
CN 1347319A · 2002 [cited by applicant]
CN 1104978C · 2003 [cited by applicant]
CN 1184978C · 2005 [cited by applicant]
CN 1972698A · 2007 [cited by applicant]
CN 101674730A · 2010 [cited by applicant]
CN 101678043A · 2010 [cited by applicant]
CN 101969769A · 2011 [cited by applicant]
CN 102164884A · 2011 [cited by applicant]
CN 104224823A · 2014 [cited by applicant]
CN 105050594A · 2015 [cited by applicant]
CN 106038532A · 2016 [cited by applicant]
CN 106459646A · 2017 [cited by applicant]
CN 106858066A · 2017 [cited by applicant]
CN 108253621A · 2018 [cited by applicant]
CN 109480284A · 2019 [cited by applicant]
CN 111655244A · 2020 [cited by applicant]
CN 111867576A · 2020 [cited by applicant]
CN 112262936A · 2021 [cited by applicant]
DE 102017210992A1 · 2019 [cited by applicant]
EP 0008700A1 · 1980 [cited by applicant]
EP 1112711A1 · 2001 [cited by applicant]
EP 1178748A1 · 2002 [cited by applicant]
EP 1827412A1 · 2007 [cited by applicant]
EP 1915144A2 · 2008 [cited by applicant]
EP 2283834A2 · 2011 [cited by applicant]
EP 1755743B1 · 2013 [cited by applicant]
EP 2976073A1 · 2016 [cited by applicant]
EP 3094321A1 · 2016 [cited by applicant]
EP 3366173A2 · 2018 [cited by applicant]
EP 3446045A1 · 2019 [cited by applicant]
FR 2997302A1 · 2014 [cited by applicant]
GB 2391493A · 2004 [cited by applicant]
ID 201701176 · 2017 [cited by applicant]
JP 11060434A · 1999 [cited by applicant]
JP 2002521330A · 2002 [cited by applicant]
JP 2004035417A · 2004 [cited by applicant]
JP 2008127369A · 2008 [cited by applicant]
JP 5030553B2 · 2012 [cited by applicant]
JP 2015042644A · 2015 [cited by applicant]
JP 5690261B2 · 2015 [cited by applicant]
JP 2015514104A · 2015 [cited by applicant]
JP 2015102323A · 2015 [cited by applicant]
JP 2016514725A · 2016 [cited by applicant]
JP 2016121128A · 2016 [cited by applicant]
JP 2017046688A · 2017 [cited by applicant]
JP 2018158897A · 2018 [cited by applicant]
JP 2018158898A · 2018 [cited by applicant]
JP 2018158899A · 2018 [cited by applicant]
JP 2019533010A · 2019 [cited by applicant]
JP 2020502652A · 2020 [cited by applicant]
JP 2020527583A · 2020 [cited by applicant]
JP 2021504476A · 2021 [cited by applicant]
JP 2021506294A · 2021 [cited by applicant]
JP 2021127322A · 2021 [cited by applicant]
JP 2021193945A · 2021 [cited by applicant]
RU 2345546C2 · 2009 [cited by applicant]
WO 8703808A1 · 1987 [cited by applicant]
WO 9841200A1 · 1998 [cited by applicant]
WO 0004895A2 · 2000 [cited by applicant]
WO 0015216A1 · 2000 [cited by applicant]
WO 0069315A1 · 2000 [cited by applicant]
WO 0370823A2 · 2003 [cited by applicant]
WO 2005077348A1 · 2005 [cited by applicant]
WO 2005107724A1 · 2005 [cited by applicant]
WO 2006029577A1 · 2006 [cited by applicant]
WO 2006061624A1 · 2006 [cited by applicant]
WO 2007115282A2 · 2007 [cited by applicant]
WO 2007138322A1 · 2007 [cited by applicant]
WO 2008005818A1 · 2008 [cited by applicant]
WO 2008021394A2 · 2008 [cited by applicant]
WO 2008024408A2 · 2008 [cited by applicant]
WO 2009089144A1 · 2009 [cited by applicant]
WO 2010021766A1 · 2010 [cited by applicant]
WO 2010104595A1 · 2010 [cited by applicant]
WO 2011101171A1 · 2011 [cited by applicant]
WO 2012019295A1 · 2012 [cited by applicant]
WO 2012024611A1 · 2012 [cited by applicant]
WO 2013057506A1 · 2013 [cited by applicant]
WO 2013150153A1 · 2013 [cited by applicant]
WO 2014153415A2 · 2014 [cited by applicant]
WO 2014153416A1 · 2014 [cited by applicant]
WO 2015063140A1 · 2015 [cited by applicant]
WO 2015071811A1 · 2015 [cited by applicant]
WO 2015156865A1 · 2015 [cited by applicant]
WO 2016123229A1 · 2016 [cited by applicant]
WO 2016149687A1 · 2016 [cited by applicant]
WO 2017156446A1 · 2017 [cited by applicant]
WO 2017165443A1 · 2017 [cited by applicant]
WO 2017165445A1 · 2017 [cited by applicant]
WO 2017182664A1 · 2017 [cited by applicant]
WO 2017184788A1 · 2017 [cited by applicant]
WO 2017208217A2 · 2017 [cited by applicant]
WO 2018055388A1 · 2018 [cited by applicant]
WO 2018089863A1 · 2018 [cited by applicant]
WO 2018114309A1 · 2018 [cited by applicant]
WO 2018132189A1 · 2018 [cited by applicant]
WO 2018175879A1 · 2018 [cited by applicant]
WO 2018187324A1 · 2018 [cited by applicant]
WO 2018187852A1 · 2018 [cited by applicant]
WO 2019018683A1 · 2019 [cited by applicant]
WO 2019099531A1 · 2019 [cited by applicant]
WO 2019104082A1 · 2019 [cited by applicant]
WO 2019108683A1 · 2019 [cited by applicant]
WO 2019118624A1 · 2019 [cited by applicant]
WO 2019200132A1 · 2019 [cited by applicant]
WO 2019204148A1 · 2019 [cited by applicant]
WO 2019237152A1 · 2019 [cited by applicant]
WO 2019237185A1 · 2019 [cited by applicant]
WO 2019245912A1 · 2019 [cited by applicant]
WO 2020041871A1 · 2020 [cited by applicant]
WO 2020092451A1 · 2020 [cited by applicant]
WO 2020257055A1 · 2020 [cited by applicant]
WO 2021178547A1 · 2021 [cited by applicant]
WO 2022040644A2 · 2022 [cited by applicant]
WO 2022232469A1 · 2022 [cited by applicant]
Supplementary European Search Report received for EP Patent Application No. 17786592.0, mailed on Nov. 25, 2019, 10 pages. [cited by applicant]
Tanaka, J., et al., “Significance of Blood Ketone Body Ration as an indicator of Hepatic Cellular Energy Status in Jaundiced Rabbits”, Gastroenterology, 1979, vol. 76, No. 4, pp. 691-696. [cited by applicant]
The Medical Republic, 2018, Sustained Release Sodium Butyrate Supplement Now Available to Support Management of GI Disorders, https://medicalrepublic.com.au/ sustained-release-sodium-butyrate-supplement-now-available-su… [cited by applicant]
Tisdale, “Reduction of weight loss and tumour size in a cachexia model by a high fat diet”, British Journal of Cancer, Jul. 1987, vol. 56, p. 39-43. [cited by applicant]
Tsai et al., “Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes” life Sciences 78 (2006) pp. 1385-1391. [cited by applicant]
U.S. Appl. No. 62/324,798, filed Apr. 19, 2016, Lowery, priority document to U.S. Pat. No. 11,173,138. [cited by applicant]
Vandenberghe et al. in Can. J. Physiol. Pharmacol. 95: 455-458 (2017) (Published at www.nrcresearchpress .com/cjpp on Nov. 25, 2016). (Year: 2016). [cited by applicant]
Veech, “The Therapeutic Implications of Ketone Bodies: The Effects of Ketone Bodies in Pathological Conditions: Ketosis, Ketogenic Diet, Redox States, Insulin Resistance, and Mitochondrial Metabolism”, Prostaglandins Le… [cited by applicant]
Veech, et al., “Ketone Bodies Mimic the Life Span Extending Properties of Caloric Restriction”, IUBMB Life Feb. 8, 2017. [cited by applicant]
Vorgerd, M. And J. Zange. Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle. Acta Myologica, 2007; XXVI; pp. 61-63. [cited by applicant]
Walton, G. et al. A randomised, double-blind, placebo controlled cross-over study to determine the gastrointestinal effects of consumption of arabinoxylan-oligosaccharides enriched bread in healthy volunteers, 2012, Nut… [cited by applicant]
Wang et al. Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors, 2024, Jou… [cited by applicant]
Williams et al., “The Chemistry of the Ketogenic Diet: Updates and Opportunities in Organic Synthesis”, Int J Mol Sci., May 15, 2021, vol. 22, No. 10, 5230, pp. 1-18. [cited by applicant]
WO2009045481, Pan et al. Published Apr. 9, 2009 Listed in this section as citation type “foreign” does not allow for any appropriate country code for “WO” documents. [cited by applicant]
Wu et al., “Medium-Chain Triglycerides in Infant Formulas and Their Relation to Plasma Ketone Body Concentrations,” Pediatric Research, vol. 20, No. 4, (1986), pp. 338-341. [cited by applicant]
Yang Y. et al., Role of Adherent-Invasive [cited by applicant]
Yang Yue et al., “Research on sarcopenic obesity”, Chinese Journal of Modern Medicine, vol. 20, No., 3, Mar. 25, 2018, pp. 98-101. [cited by applicant]
Yang Zeyi, “Biochemistry of sports nutrition scientific research progress”, Mar. 31, 2004, vol. 23, No. 2, pp. 158-165. [cited by applicant]
Zaleski, A. et al., Butyric acid in irritable bowel syndrome, 2013, Prz Gastroenterol, 8(6), 350-353 (Year: 2013). [cited by applicant]
Zare et al., “Wake-Promoting Agents, Insights into Clinical Use and Molecular Perspectives,” Journal of Advanced Medical Sciences and Applied Technologies (JAMSAT), vol. 2, 2016, pp. 129-140. [cited by applicant]
Zeng Jing et al., “B-hydroxy-3-methyl—The clinical effects and mechanism”, vol. 2, No. 2, Jun. 9, 2015, pp. 57-62. [cited by applicant]
Kossoff, Eric H. et al. “Optimal Clinical Management of Children Receiving the Ketogenic Diet: Recommendations of the International Ketogenic Diet Study Group.” Epilepsia, Feb. 2009; 50(2):304-17. Epub Sep. 23, 2008. [cited by applicant]
Krotkiewski, “Value of VLCD Supplementation with Medium Chain Triglycerides”, Int J Obes Relat Metab Disord, Sep. 2001, 25 (9), pp. 1393-1400. [cited by applicant]
Lang Chaochun, “Healthy fitness and exercise prescription”, Nov. 30, 2013, p. 201. [cited by applicant]
Lannotti et al., “Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice”, Br J Pharmacol, May 2019, vol. 176, No. 10, pp. 1568-1584. [cited by applicant]
Lile et al. Drug Alcohol Depend. 2012, 122 (1-2), 61-69. [cited by applicant]
Lonza, Duocap Capsules, Feb. 16, 2018, https ://web .archive .org/web/20180216001656/https://www.capsugel.com/consumer-health-nutrition-products/duocap-capsules (Year: 2018). [cited by applicant]
Luis Villasenor, “Supplements and Ketogenic Diets—Facts and Myths”, Retrieved from https://www.ketogains.com/2015/09/supplements-and-ketogenic-diets-facts-and-myths/, Sep. 18, 2015, pp. 15. [cited by applicant]
Lytra. G. et al., “Distribution and Organoleptic Impact of Ethyl 3-Hydroxybutanoate Enantiomers in Wine,” J. Agric. Food Chem, vol. 63, Issue 48, 2015, pp. 10484-10491. [cited by applicant]
Maalouf M et al., “Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation,” Neuroscience, New York, NY, US, vol. 145, Issue 1, Mar.… [cited by applicant]
Maalouf Met al., “The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies,” Brain Research Reviews, Elsevier, NL, vol. 59, No. 2, Mar. 1, 2009, pp. 293-315. [cited by applicant]
Maguire et al., “Gut dysbiosis, leaky gut, and intestinal epithelial proliferation in neurological disorders: towards the development of a new therapeutic using amino acids, prebiotics, probiotics, and postbiotics”, Rev… [cited by applicant]
Malo, M. S. et al., Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota, 2010, Gut, 59, 1476-1484 (Year: 2010). [cited by applicant]
Mangels D.R. et al, “Catechins as Potential Mediators of Cardiovascular Health”, Translational Sciences, vol. 37, No. 5, May 1, 2017, pp. 757-763. [cited by applicant]
McFarland, L. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review, 2014, BMJ Open, 4(8): 1-18 (Year: 2014). [cited by applicant]
Murray, Andrew J., et al. “Novel ketone diet enhances physical and cognitive performance”, The FASEB Journal, No. Dec. 30, 2016. [cited by applicant]
National Center for Biotechnology Information. PubChem Compound Summary for CID 441, 3-Hydroxybutyric acid, https://pubchem.ncbi.nlm.nih.gov/compound/3-Hydroxybutyric-acid. (Year: 2005). [cited by applicant]
Newman et al. “B-Hydroxybutyrate: A Signaling Metabolite”, Annu Rev Nutr., Aug. 21, 2017, pp. 1-30. [cited by applicant]
Newman et al., “B-hydroxybutyrate: Much more than a metabolite”, Diabetes Res Clin Pract., Nov. 2014. [cited by applicant]
Non-Final Rejection Mailed on Sep. 9, 2020 for U.S. Appl. No. 16/783,956. [cited by applicant]
Nova Max Plus Glucose and Ketone Testing with One Monitor. Downloaded Apr. 1, 2015. http://www.novacares.com/nova-max-plus/. [cited by applicant]
O'Mailey et al, Appl. Physiol. Nutr. Metab. 42: 1031-1035 (2017) Published at www.NRCRESEARCHPRESS.com/APNM on Jul. 27, 2017. [cited by applicant]
O'Meara, Cyndi, Changing Habits, Ketosis—Can we achieve it in a pill?, https://changinghabits. com.au/ketosis-can-we-achieve-it-in-a-pill/, 12 pages, (Jan. 13, 2017). [cited by applicant]
Office Action received for European Patent Application No. 17786592.0, mailed on Jun. 17, 2022, 7 pages. [cited by applicant]
Office Action received for European Patent Application No. 17786592.0, mailed on Sep. 25, 2020, 7 pages. [cited by applicant]
Office Action received for European Patent Application No. 19788264.0, mailed on Mar. 13, 2024, 5 pages. [cited by applicant]
Office Action received for European Patent Application No. 19880284.5, mailed on Nov. 9, 2023, 5 pages. [cited by applicant]
Office Action received for European Patent Application No. 20805593.9, mailed on Dec. 22, 2023, 7 pages. [cited by applicant]
Paraxanthine-Pubchem—2023 (Year: 2023). [cited by applicant]
Parker, Steve, “Ketogenic Mediterraanean Diet: Version 2.3,” Nov. 23, 2010, pp. 1-3. (Year: 2010). [cited by applicant]
Partial supplementary European search report (EPO Form 1507US) issued by the European Patent Office on Sep. 21, 2016 for corresponding European Application No. 14770025.6. [cited by applicant]
Pete J Cox et al., “Acute nutritional ketosis: implications for exercise performance and metabolism,” Extreme Physiology & Medicine, vol. 3, Issue 1, Dec. 1, 2014, pp. 1-9. [cited by applicant]
Precision Xtra vs. NovaMax Plus: Ketone Meter Evaluation. Jimmy Moore's Livin' La Vida Low Garb Blog. Downloaded Apr. 1, 2015. http://livinlavidalowcarb.com/blog/precision-xtra-vs-novamax-plus-ketone-meter-evaluation/15… [cited by applicant]
Pubchem, “Acetoacetic acid” Electronic Resource: https://pubchem.ncbi.nim.nih.gov/compound/Acetoacetic-acid, Retrieved on Sep. 3, 2019. [cited by applicant]
Rho et al. “Acetoacetate, Acetone, and Dibenzylamine (A Contaminant in L-(+)-Beta-Hydroxybutyrate) Exhibit Direct Anticonvulsant Actions in Vivo”, Epilepsia, Raven Press Ltd, New York, US, vol. 43, No. 4, Apr. 1, 2002 (… [cited by applicant]
Riccio et al. The human gut microbiota is neither an organ nor a commensal, 2020, FEBS Letters, 594(20): 3262-3271 (Year: 2020). [cited by applicant]
Rich A.J., “Ketone Bodies as Substrates,” Proceedings of the Nutrition Society (1990), vol. 49, 361-373. [cited by applicant]
Robson et al. Expert Opin. Drug Saf. (2011), vol. 10, pp. 675-685 (Year: 2011). [cited by applicant]
Roeder, Lois M., et al. The Effects of Ketone Bodies, Bicarbonate, and Calcium on Hepatic Mitochondrial Ketogenesis. Archives of Biochemistry and Biophysics, vol. 217, No. 2, Sep. pp. 460-467, 1982. [cited by applicant]
Rogers GB et al. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways, 2016, Molecular Psychiatry, 21: 738-748 (Year: 2016). [cited by applicant]
Sajewicz et al. In Journal of Liquid Chromatography & Related Technologies, 33:1047-1057 (2010) (Year: 2010). [cited by applicant]
Sanchez, J. I. et al. Arabinoxylan-oligosaccharides (AXOS) affect the protein/carbohydrate fermentation balance and microbial population dynamics of the Simulator of Human Intestinal Microbial Ecosystem, 2009, Microbial… [cited by applicant]
Sara, How do you know which product is right for you? How to choose exogenous ketones, https://ketosupplements.co.uk/how-to-choose-exogenous-ketones/, 10 pages, (Sep. 25, 2017). [cited by applicant]
Search Report and Written Opinion issued by the Intellectual Property Office of Singapore on Apr. 18, 2016 for corresponding Singapore Application No. 11201506780R. [cited by applicant]
Serum Ketones Test. MedlinePlus Medical Encyclopedia. Downloaded Apr. 1, 2015. http://www.nlm.nih.gov/medlineplus/ency/article/003498.htm. [cited by applicant]
Shigeno et al. in Biosci. Biotech. Biochem., 56(2), 320-323 (1992) (Year: 1992). [cited by applicant]
Short, Jay, Effects of A Ketone/Caffeine Supplement On Cycling and Cognitive Performance, Master's thesis, Ohio State University, 61 pages, (Jan. 1, 2017). [cited by applicant]
Slavin, J. Fiber and Prebiotics: Mechanisms and Health Benefits, 2013, Nutrients, 5: 1417-1425 (Year: 2013). [cited by applicant]
Sorensen et al. (“Simultaneous determination of B-hydroxybutyrate and B-hydroxy-B-methylbutyrate in human whole blood using hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry”, Clinical … [cited by applicant]
Stefan et al., “The Effects of Exogenous Beta-Hydroxybutyrate Supplementation on Metrics of Safety and Health”, International Journal of Nutrition and Food Sciences, vol. 9, No. 6, Nov. 2020, pp. 154-162. [cited by applicant]
Stubbs et al., “On the Metabolism of Exogenous Ketones in Humans”, frontiers in Physiology, vol. 8, 2017, 13 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2017/021886, mailed on Sep. 20, 2018, 9 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2018/062093, mailed on Jun. 4, 2020, 6 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2018/062096, mailed on Jul. 2, 2020, 8 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/027214, mailed on Oct. 29, 2020, 09 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/048357, mailed on Mar. 11, 2021, 08 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/048364, mailed on Mar. 11, 2021, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/016952, mailed on Aug. 26, 2021, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/017552, mailed on Aug. 26, 2021, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/017555, mailed on Aug. 26, 2021, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/017556, mailed on Aug. 26, 2021, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/033159, mailed on Nov. 25, 2021, 6 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/017078, mailed on Aug. 18, 2022, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/045186, mailed on Mar. 9, 2023, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/050302, mailed on Mar. 2, 2023, 8 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/063559, mailed on Jul. 6, 2023, 6 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2023/020407, mailed on Nov. 7, 2024, 7 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US17/2846 dated Jul. 5, 2017 (9 pages). [cited by applicant]
International Search Report and Written Opinion issued in PCT/US19/48364 dated Nov. 15, 2019. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US17/28466, mailed on Jul. 5, 2017, 8 pages. [cited by applicant]